US2012087952A1PendingUtilityA1

Pulmonary Delivery in Treating Disorders of the Central Nervous System

56
Assignee: BARTUS RAYMOND TPriority: Sep 19, 2000Filed: Sep 13, 2011Published: Apr 12, 2012
Est. expirySep 19, 2020(expired)· nominal 20-yr term from priority
A61P 25/22A61P 25/08A61P 25/16A61P 25/06A61P 25/00A61P 25/24A61P 25/18A61P 25/28A61K 9/008A61K 31/4045A61K 9/007A61K 9/14A61K 9/16A61P 11/00A61K 9/0075
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm 3 . In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.

Claims

exact text as granted — not AI-modified
1 . A method for delivering a drug to the pulmonary system of a patient comprising, administering a drug selected from alprazolam and loxapine to the respiratory tract of the patient in need of the drug, wherein the drug is delivered to the deep lung of the pulmonary system and wherein the drug is delivered in a dose that is therapeutically effective for treating a disorder of the central nervous system. 
     
     
         2 . The method of  claim 1 , wherein the dose that is therapeutically effective for treating a disorder of the central nervous system is at least about two times less than the dose required by oral administration of the drug. 
     
     
         3 . The method of  claim 1 , wherein the drug is delivered to the pulmonary system in the form of particles. 
     
     
         4 . The method of  claim 3 , wherein the particles delivered to the pulmonary system have an aerodynamic diameter ranging from about 1 μm to about 5 μm. 
     
     
         5 . The method of  claim 3 , wherein the particles delivered to the pulmonary system have an aerodynamic diameter in the range from about 1 μm to about 3 μm. 
     
     
         6 . The method of  claim 3 , wherein the particles deliver at least about 10 milligrams of the drug to the pulmonary system. 
     
     
         7 . The method of  claim 1 , wherein the drug is delivered to the pulmonary system in a single, breath activated step. 
     
     
         8 . The method of  claim 3 , wherein the particles consist essentially of the drug. 
     
     
         9 . The method of  claim 3 , wherein the particles consist of the drug.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.